GlassScriptPhysician profile
Adrian N Cade
NPI 1588176069
$4,927.52
in general payments reported to CMS, 2019-2025
22 companies · $1,706 in 2025
The $1,706 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $532 · 2023: $967 · 2024: $1,476 · 2025: $1,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,979 · Consulting Fee: $115 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,979.08 |
| Consulting Fee | $115.00 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $730.98 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $609.68 | 2021-2025 | Spravato |
| Abbvie INC. | $473.63 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $448.42 | 2022-2025 | Rexulti |
| Corium, LLC | $435.87 | 2021-2025 | Azstarys |
| Lundbeck LLC | $330.63 | 2021-2025 | Rexulti, Brintellix |
| Axsome Therapeutics, INC. | $271.19 | 2023-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $265.57 | 2023-2025 | Dyanavel Xr |
| Harmony Biosciences LLC | $228.77 | 2023-2024 | Wakix |
| Teva Pharmaceuticals USA, INC. | $227.60 | 2023 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $218.78 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $120.51 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.79 | 2022-2025 | Caplyta |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $73.13 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $61.03 | 2024-2025 | Fanapt, Hetlioz |
| Collegium Pharmaceutical, INC. | $58.64 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $48.39 | 2022-2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $34.54 | 2023-2025 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $26.10 | 2022-2023 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $18.88 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.39 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Cade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.